Transrepression and transactivation potencies of inhaled glucocorticoids

Pharmazie

Volumn 63, Issue 12, 2008, Pages 893-898

  Dirks, N L ^a   Li, S ^a   Huth, B ^a   Hochhaus, G ^b   Yates, C R ^a   Meibohm, Bernd ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CICLESONIDE; DEXAMETHASONE; FLUNISOLIDE; FLUOCORTOLONE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MOMETASONE FUROATE; PREDNISOLONE; TRANSCRIPTION FACTOR AP 1; GLUCOCORTICOID;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; DRUG POTENCY; ENZYME INDUCTION; GENE EXPRESSION; GENETIC TRANSFECTION; GLUCOCORTICOID RESPONSIVE ELEMENT; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; PLASMID; PROMOTER REGION; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; REPORTER GENE; SECRETED ALKALINE PHOSPHATASE REPORTER GENE; TRANSACTIVATION; ALGORITHM; CELL LINE; COMPARATIVE STUDY; DNA RESPONSIVE ELEMENT; DRUG EFFECT; EPITHELIUM CELL; GENETICS; INHALATIONAL DRUG ADMINISTRATION; TRANSCRIPTION INITIATION;

ADMINISTRATION, INHALATION; ALGORITHMS; CELL LINE; EPITHELIAL CELLS; GENES, REPORTER; GLUCOCORTICOIDS; HUMANS; NF-KAPPA B; PLASMIDS; RESPONSE ELEMENTS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 61449099468     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.8638     Document Type: Article

References (38)

1. Adcock IM, Nasuhara Y, Stevens DA, Barnes PJ (1999) Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol 127: 1003-1011.
2. Atsuta J, Plitt J, Bochner BS, Schleimer RP (1999) Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am J Respir Cell Mol Biol 20: 643-650.
3. Austin RJ, Maschera B, Walker A, Fairbairn L, Meldrum E, Farrow SN, Uings IJ (2002) Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J 20: 1386-1392.
4. Barnes PJ, Adcock IM (1998) Transcription factors and asthma. Eur Respir J 12: 221-234.
5. Barnes PJ, Adcock IM (2003) How do corticosteroids work in asthma? Ann Intern Med 139: 359-370.
6. Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071.
7. Barnes PJ, Pedersen S, Busse WW (1998) Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157: S1-53.
8. Belvisi MG, Brown TJ, Wicks S, Foster ML (2001) New Glucocorticosteroids with an improved therapeutic ratio? Pulm Pharmacol Ther 14: 221-227.
9. Bladh LG, Liden J, Dahlman-Wright K, Reimers M, Nilsson S, Okret S (2005) Identification of endogenous glucocorticoid repressed genes differentially regulated by a glucocorticoid receptor mutant able to separate between nuclear factor-jB and activator protein-1 repression. Mol Pharmacol 67: 815-826.
10. Czock D, Keller F, Rasche FM, Haussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44: 61-98.
11. Dahl R (2006) Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 100: 1307-1317.
12. De Bosscher K, Vanden Berghe W, Haegeman G (2003) The interplay between the glucocorticoid receptor and nuclear factor-jB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 24: 488-522.
13. Derendorf H, Hochhaus G, Meibohm B, Mollmann H, Barth J (1998) Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101: S440-446.
14. Derendorf H, Mollmann H, Hochhaus G, Meibohm B, Barth J (1997) Clinical PK/PD modelling as a tool in drug development of corticosteroids. Int J Clin Pharmacol Ther 35: 481-488.
15. Dobbs LG (1994) Alveoli and airways: possible interactions in the pathogenesis of asthma. Am J Respir Crit Care Med 150: S31-32.
16. Hayashi R, Wada H, Ito K, Adcock IM (2004) Effects of glucocorticoids on gene transcription. Eur J Pharmacol 500: 51-62.
17. Hochhaus G (2004) New developments in corticosteroids. Proc Am Thorac Soc 1: 269-274.
18. Högger P, Erpenstein U, Rohdewald P, Sorg C (1998) Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res 15: 296-302.
19. Jaffuel D, Demoly P, Gougat C, Balaguer P, Mautino G, Godard P, Bousquet J, Mathieu M (2000) Transcriptional potencies of inhaled glucocorticoids. Am J Respir Crit Care Med 162: 57-63.
20. Jaffuel D, Roumestan C, Balaguer P, Henriquet C, Gougat C, Bousquet J, Demoly P, Mathieu M (2001) Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids. Steroids 66: 597-604.
21. Kraft M (1999) The distal airways: are they important in asthma? Eur Respir J 14: 1403-1417.
22. Mager DE, Moledina N, Jusko WJ (2003) Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. J Pharm Sci 92: 1521-1525.
23. Martin RJ (2002) Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 109: S447-460.
24. Moon KY, Hahn BS, Lee J, Kim YS (2001) A cell-based assay system for monitoring NF-jB activity in human HaCat transfectant cells. Anal Biochem 292: 17-21.
25. National Heart Blood and Lung Institute (2005) Global Initiative for Asthma - Global Strategy for Asthma Management and Prevention. National Institutes of Health, Bethesda, MD.
26. Newton R, Holden NS (2007) Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 72: 799-809.
27. Pelaia G, Vatrella A, Cuda G, Maselli R, Marsico SA (2003) Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci 72: 1549-1561.
28. Rohatagi S, Arya V, Zech K, Nave R, Hochhaus G, Jensen BK, Barrett JS (2003) Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 43: 365-378.
29. Rohdewald P, Mollman HW, Hochhaus G (1986) Affinities of glucocorticoids for glucocorticoid receptors in the human lung. Agents Actions 17: 290-291.
30. Roumestan C, Henriquet C, Bousquet J, Mathieu M (2003) Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies. Clin Exp Allergy 33: 895-901.
31. Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, Uings IJ, Gray DW (2007) Pharmacological properties of the enhancedaffinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 293: L660-667.
32. Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23-43.
33. Smith CL, Kreutner W (1998) In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 48: 956-960.
34. Stellato C, Atsuta J, Bickel CA, Schleimer RP (1999) An in vitro comparison of commonly used topical glucocorticoid preparations. J Allergy Clin Immunol 104: 623-629.
35. Umland SP, Nahrebne DK, Razac S, Beavis A, Pennline KJ, Egan RW, Billah MM (1997) The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. J Allergy Clin Immunol 100: 511-519.
36. Valotis A, Neukam K, Elert O, Hogger P (2004) Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 93: 1337-1350.
37. Würthwein G, Rehder S, Rohdewald P (1992) Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss 5/137: 161-167.
38. Yang TT, Sinai P, Kitts PA, Kain SR (1997) Quantification of gene expression with a secreted alkaline phosphatase reporter system. Biotechniques 23: 1110-1114.